Steris Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 1, 2021, reports on material events for STERIS Plc (STERIS), a global provider of infection prevention and patient safety solutions. The primary event is the completion of a senior notes offering on April 1, 2021, to facilitate the proposed acquisition of Cantel Medical Corp. (Cantel).
Key Financial Metrics and Capital Structure
The filing details a significant debt issuance rather than operational financial results for a specific period.
- Total Offering Size: $1,350,000,000 aggregate principal amount.
- Net Proceeds: Approximately $1,330.5 million after underwriters' discounts and estimated expenses.
- Tranche 1 (2031 Notes): $675,000,000 principal; 2.700% interest rate; matures March 15, 2031.
- Tranche 2 (2051 Notes): $675,000,000 principal; 3.750% interest rate; matures March 15, 2051.
- Interest Payments: Payable semi-annually on March 15 and September 15, commencing September 15, 2021.
- Guarantees: Notes are guaranteed jointly and severally on a senior unsecured basis by STERIS plc, STERIS Corporation, and STERIS Limited.
Material Changes and Use of Proceeds
The issuance represents a material change in the company's capital structure. STERIS intends to use the net proceeds, combined with borrowings under existing credit facilities, for the following purposes:
- Funding the cash consideration for the acquisition of Cantel Medical Corp.
- Refinancing, prepayment, or redemption of certain existing indebtedness of Cantel and its subsidiaries.
- Covering transaction expenses, general corporate expenses, and working capital needs.
Special Mandatory Redemption: If the Cantel acquisition is not consummated or the agreement is terminated on or prior to April 12, 2022, the Issuer is required to redeem all outstanding 2031 Notes at 101% of principal plus accrued interest. The 2051 Notes are not subject to this special mandatory redemption.
Outlook, Risks, and Regulatory Status
Acquisition Status: The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) expired on March 31, 2021. STERIS anticipates completing the acquisition during the first quarter of fiscal year 2022 (ending June 30, 2021), subject to closing conditions.
Key Risks and Contingencies:
- Acquisition Failure: Risks include failure to obtain stockholder approval, regulatory prohibitions, or termination of the merger agreement.
- Integration Risks: Potential inability to realize cost savings or synergies, disruption to operations, and retention of key personnel.
- Financial Risks: Risks related to the accounting and tax treatment of the redomiciliation to Ireland and the acquisition itself.
- Market and Operational Risks: Impact of the COVID-19 pandemic, changes in tax laws, international unrest, and supply chain disruptions.
Investor Verification Checklist
- Verify the final closing date of the Cantel Medical Corp. acquisition and confirm if the April 12, 2022, deadline for the Special Mandatory Redemption of the 2031 Notes is relevant.
- Review the full text of the Indenture (Exhibit 4.1) and Supplemental Indenture (Exhibit 4.2) for detailed covenants regarding liens, sale-leaseback transactions, and events of default.
- Monitor the status of the Form S-4 registration statement and the proxy statement/prospectus for the acquisition to assess shareholder approval progress.
- Assess the impact of the new debt load on STERIS's leverage ratios and liquidity position in subsequent quarterly filings.
- Confirm the final tax treatment of the redomiciliation to Ireland and its effect on consolidated tax liabilities.